Discovery of Tetrahydroisoquinoline-Based CXCR4 Antagonists

Citations Over TimeTop 19% of 2013 papers

Abstract

A de novo hit-to-lead effort involving the redesign of benzimidazole-containing antagonists of the CXCR4 receptor resulted in the discovery of a novel series of 1,2,3,4-tetrahydroisoquinoline (TIQ) analogues. In general, this series of compounds show good potencies (3-650 nM) in assays involving CXCR4 function, including both inhibition of attachment of X4 HIV-1IIIB virus in MAGI-CCR5/CXCR4 cells and inhibition of calcium release in Chem-1 cells. Series profiling permitted the identification of TIQ-(R)-stereoisomer 15 as a potent and selective CXCR4 antagonist lead candidate with a promising in vitro profile. The drug-like properties of 15 were determined in ADME in vitro studies, revealing low metabolic liability potential. Further in vivo evaluations included pharmacokinetic experiments in rats and mice, where 15 was shown to have oral bioavailability (F = 63%) and resulted in the mobilization of white blood cells (WBCs) in a dose-dependent manner.

Related Papers

• → Tetrahydroisoquinoline alkaloids of the Mexican columnar cactus Pachycereus Weberi(1980)24 cited
• → The preparation and oxidative dimerisation of 2‐acetyl‐7‐hydroxy‐1,2,3,4‐tetrahydroisoquinoline. A new approach to tetrahydroisoquinoline synthesis(1985)14 cited
• Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
• → ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ(2024)
• → Antidopaminergic Effects of Putative Endogenous MPTP-Like Agents: 1,2,3,4-Tetrahydroisoquinoline and 1-Methyl-6,7-Dihydroxy-l,2,3,4-Tetrahydroisoquinoline(2000)